Search

There are different types of treatment for breast cancer, including surgery, chemotherapy, radiotherapy, hormone therapy, immunotherapy, and targeted therapy. Deciding on the types of treatment depends on several factors, such as the stage and grade of cancer, biomarkers, and general health of patients. The seventh volume of the “Interdisciplinary Cancer Research” series, entitled “Breast Cancer Treatment: An Interdisciplinary Approach” publishes comprehensive reviews on different treatment opportunities on breast cancer. An update on treatment of triple-negative breast cancer and ductal carcinoma in situ is provided. Ablative breast cancer surgery, radiotherapy, and percutaneous breast cancer treatment are explained. Promising hormone immunotherapy combination as well as targeted therapies for breast cancer is also discussed. This interdisciplinary series is of special value to researchers working on oncology. This is the main concept of Cancer Immunology Project (CIP), which is a part of Universal Scientific Education and Research Network (USERN). This interdisciplinary book will be of special value to researchers and oncologists who wish to extend their knowledge on breast cancer treatment.

Cancer cells exist in an ever-changing “ecology” and are subject to evolutionary pressures just like any species in nature. This edited book explores the following themes: 1) how the dynamics of mutation, epigenetics, and gene expression noise are sources of genetic diversity; 2) how scarce resources influence cancer therapy resistance; 3) how predator-prey dynamics are mirrored in immune-cancer cross-talk; 4) how cancer cells parallel niche construction theory; 5) how changing fitness landscapes enable cancer growth; and 6) how cancer cells interact within the body. The book is a resource for understanding cancer as a disease of multicellularity grounded in evolutionary principles. By using this knowledge, researchers are starting to exploit these behaviors for treatment paradigms.Key Features Bridges disciplines exemplifying the ways disparate fields create new perspectives when integrated. Offers insights from leading scholars in cancer biology, ecology and evolutionary biology. Provides a timely recognition by oncologists that evolutionary paradigms are crucial for breakthroughs in cancer treatment. Integrates basic and applied sciences of oncology and evolutionary biology.

This book now published in its fully updated second edition comprehensively summarizes the current state of knowledge on malignancies of the gastrointestinal tract and highlights the latest efforts in multimodality treatment options before and after surgery, important ongoing trials as well as future areas of investigation. Dedicated organ-based chapters evaluate current treatments and management and provide information on incidence, etiology and biological characteristics. The state of the art in the radiologic and endoscopic staging of gastrointestinal malignancies is described, and guidance is offered on the role of interventional radiology and interventional gastroenterology in the treatment of these challenging tumors. In addition, the book explores novel and evolving treatments, including Immunotherapy, personalized systemic therapy and minimally invasive surgical and radiology techniques, and addresses patient-reported outcomes and survivorship challenges. It will be of benefit to all surgeons, oncologists and other specialists who treat these malignancies, as well as to trainees looking to increase their understanding of the field.

This book describes intraoperative flow cytometry in solid tumours. Intraoperative flow cytometry is an innovative technique for assessing tumour margins and grade of malignancy intraoperatively. The authors have been working on this procedure for more than 14 years and have introduced it in the surgery of intracranial tumours, breast cancer, liver cancer and head and neck neoplasms, as described in the book. A detailed description of the main pathological findings will be followed by an explanation of the intraoperative flow cytometry's role. In each chapter, information will be provided to stimulate further research on this topic. The book will also include new topics that have not been published till now. The book is aimed at neurosurgeons, general surgeons, ENT specialists, breast surgeons, radiologists, pathologists, oncologists, biologists, biochemists and scientists working with on flow cytometry.

CANCER CONSULT New edition covering the specialties of hematology, oncology and cellular therapy, now in two volumes Cancer Consult: Expertise in Clinical Practice, Volume 1: Solid Tumors & Supportive Care, Second Edition includes hundreds of answers to practice-based questions covering the new principles of diagnosis, classification, staging, treatment, and outcomes in the rapidly advancing field of cancer. This textbook series also provides expert guidance in the areas of cancer-related uncertainties and controversies, including experience-based discussions. The book's smaller size allows for easy access during medical rounds. This volume also includes: Up-to-date, clinically relevant information on the very latest topics such as molecular techniques, targeted therapies, immunotherapy, cellular therapy and translational cancer research Sections on head, neck, thoracic, breast, GI, genitourinary, skin, gynecological and hereditary cancers, amongst other topics Streamlined, engaging content to make finding information easier and less time consuming for the reader Concise and practical expert perspectives that reference key studies References to the latest NCCN, ESMO, ASCO, and other national guidelines With its powerful focus on pragmatic clinical diagnostic, therapeutic and prognostic approaches, Cancer Consult: Expertise in Clinical Practice, Volume 1: Solid Tumors & Supportive Care, Second Edition will help keep hematology, oncology and cellular therapy practitioners up-to-date, bridging the gaps between journal and reference literature, conferences, and their existing knowledge base. It also offers clinicians, trainees, and fellows an excellent opportunity to enhance their preparation for the ABIM, hematology and oncology fellowship and recertification exams.

Using a practical, question-and-answer approach, Evidence-Based Practice of Palliative Medicine, 2nd Edition, helps you provide optimal care for patients and families who are dealing with serious illness. This unique reference focuses on patient and family/caregiver-centered care, highlighting the benefits of palliative care and best practices for delivery. The highly practical, user-friendly format sets it apart from other texts in the field, with concise, readable chapters organized around clinical questions that you're most likely to encounter in everyday care. Uniquely organized using a question-and-answer approach, making it easy to find answers to common questions asked by practitioners and patients. Up-to-date, reader-friendly chapters explore interventions, assessment techniques, treatment modalities, recommendations and guidelines, communication techniques, and available resources for palliative care. Expanded discussions on hospice in every chapter, and a new emphasis on pediatrics, with increased material on pediatric malignancies, developmental delays, cystic fibrosis, and perinatal palliative care. New chapters on wellness of the palliative care practitioner, patients with opioid use disorders, telehealth in palliative care, health disparities, rural palliative care, caring for people with hematologic malignancies, integrative and alternative therapies, LGBTQ+ populations, mobile health technologies, and national palliative care implementation strategies. High-quality evidence gathered and reviewed by leading experts in palliative medicine, including clinicians, educators, and researchers across a broad range of disciplines.Numerous algorithms throughout help you make informed decisions, and “take-home” points in every chapter provide a quick summary of key content.Any additional digital ancillary content may publish up to 6 weeks following the publication date.

Cancer is a major public health concern and one of the leading causes of death. There is no simple solution for this complex disease, therefore interdisciplinary approaches might help to find solutions to many unanswered questions and challenges about cancer. The rapid flow of interdisciplinary research in cancer during recent years has increased our understanding of the nature of cancers. Such interdisciplinary approaches could be helpful for both the diagnosis and the development of more effective therapeutic strategies.The “Interdisciplinary Cancer Research” series publishes comprehensive volumes on different cancers and presents the most updated and peer-reviewed articles on human cancers. Over the past decade, increased cancer research has greatly improved our understanding of the nature of cancerous cells which has led to the development of more effective therapeutic strategies to treat cancers. This interdisciplinary series is of special value to researchers and practitioners working on cell biology, immunology, hematology, biochemistry, genetics, oncology and related fields. This is the main concept of Cancer Immunology Project (CIP), which is a part of Universal Scientific Education and Research Network (USERN).

This is an open access book.With a wealth of exciting data emerging in this rapidly evolving field this book will review the state-of-the-art knowledge with emphasis on multidisciplinary decision and management of head and neck cancer. The book provides significant detail on a wide range of topics including: the role of new targets for treatment, immunotherapy, resistance mechanisms, standardizing molecular profiling programs, and new methods to guide therapeutic approaches. In addition different disease situations are addressed including different treatment approaches in primary disease and in recurrent and/or metastatic disease as well as new developments in pathology, surgery and reconstruction techniques, new systemic therapies in salivary gland cancer, and supportive care and follow-up.All disciplines involved in the treatment of head & neck cancer are covered with a focus on translation into daily practice. The 8th-THNO is designed for medical oncologists, head and neck surgeons, radiation oncologists, otolaryngologists, and other medical professionals involved in the treatment of patients with head and neck cancer.

This book thoroughly illustrates the designed and tailored medical approaches for tumors of the female reproductive organ. The chapters explore different cancer species such as ovarian cancer, endometrial cancer, cervical cancer, etc. Various treatment modalities such as immunotherapy and histotype-specific treatment are delivered, and it offers a chapter on how genome-wide analysis contributes to personalized treatment. It is essential to understand this concept because many molecular target drugs and the prevalence of genome-based analysis in clinical settings have enabled us to introduce valid precision medicine in the field of gynecologic oncology. Chapters explain the stream of transition from conventional standardized treatment to personalized treatment and address future perspectives.Personalization Gynecologic Oncology is a well-designed source for beginning to advanced oncologists, gynecologists, geneticists, genetic counselors, and nurses. Offering the latest treatment strategies, the Editor hopes the ideas presented here will be a foundation for further development in the field.

Une nouvelle édition actualisée et enrichie du guide de référence des investigateurs d'études et d'essais cliniques en cancérologie. Un outil indispensable : pour mieux situer les exigences statistiques (hypothèses et analyses) lors de l'élaboration de projets de recherche en cancérologie ; pour mesurer les stratégies thérapeutiques. Nos 3 coordonnateurs, Sophie Gourgou, Xavier Paoletti et Simone Mathoulin-Pélissier, ont réussi à rassembler les auteurs les plus aguerris pour ce nouvel opus, destiné aux biostatisticiens, cliniciens, biologistes, pharmaciens, datamanagers, étudiants impliqués dans le domaine de la cancérologie.

This book aims to examine all immunohistochemical and molecular pathological biomarkers that can be useful and effective in patient diagnosis, prognosis and treatment decision, especially when faced with a carcinoma of unknown primary. For this purpose, epithelial malignancies of all systems and related biomarkers are examined one by one, and to look at the subject through the metastatic regions window, biomarkers that can be used to determine the primary focus for carcinomas seen in the areas most frequently metastasized are emphasized. With this bi-directional perspective, the reader is able to find biomarkers of any type of carcinoma on a system basis, as well as access to which biomarkers can be used when faced with a metastatic carcinoma. The importance of biomarkers in patient follow-up and treatment is also conveyed through the clinician's eye, and so biomarkers are handled with a holistic approach in all aspects. This book primarily targets pathologists, as well as clinicians (oncologists and surgeons) who manage cancer patients.

Thoroughly updated to reflect major advances in the field of immuno-oncology, this second edition of Cancer Immunotherapy Principles and Practice, from the Society for Immunotherapy of Cancer (SITC), remains the definitive resource for information on tumor immunology and cancer immunotherapy treatments. An essential reference for both novice and experienced cancer researchers, oncologists, and related practitioners alike, the book not only guides readers through the fundamental scientific principles of the field all the way to translational and practical clinical applications for treating and managing oncologic disease, but also provides a comprehensive understanding of the regulatory processes that support the safe and effective delivery of immunotherapy to patients with cancer. The expanded and updated second edition now spans 68 chapters, including 12 new chapters, covering major topics and innovations that have shaped the rapid development of immunotherapy and its ascension into the standard of care as first-line treatment for a growing number of disease settings. New to this edition are chapters with deeper insight into our understanding of cancer genomics and determinants of response, immunogenic cell death, cancer and stromal cell-intrinsic pathways of immune resistance, cancer immune exclusion, adoptive cell therapy, metabolomics, tumor mutation burden, immunotherapy in combination with radiation therapy, synthetic biology, and more. Complete with detailed illustrations, tables, and key points for targeted reference, Cancer Immunotherapy Principles and Practice, Second Edition is the most comprehensive and authoritative resource for scientists and clinicians looking to expand their knowledge base of this dynamic field. Key Features: Offers key insights and perspectives on cancer immunology and immunotherapy treatments from renowned experts in the field Covers the basic principles and science behind cancer immunotherapy and tumor immunology Includes treatment strategies for a vast array of available immunotherapy classes and agents, such as cytokine therapies, oncolytic viruses, cancer vaccines, CAR T therapies, and combination immunotherapies Provides essential information on FDA-approved immunotherapies, including clinical management and outcome data related to response rates, risks, and toxicities Discusses special considerations for immunotherapy in the context of specific disease settings, including skin cancers, genitourinary cancers, gastrointestinal cancers, hepatocellular carcinomas, gynecologic malignancies, breast cancers, lung cancers, head and neck cancers, brain tumors, sarcomas, pediatric cancers, and treatments combined with radiation therapy Clarifies the complex regulatory aspects behind the development and approval of immunotherapy drugs

This textbook describes in detail the process of cancer metastasis from a single cell in the primary site through its arduous journey to the sentinel lymph node as the main gateway and beyond to distant sites. The most up-to-date knowledge on key topics in the molecular biology, diagnosis, and treatment of metastatic cancer is highlighted by a large panel of experts. The book begins with a comprehensive overview of the genetic and molecular mechanisms that promote or inhibit cancer metastasis through lymphatic pathways to lymph nodes or through vascular pathways to distant sites, providing the reader with an essential basic knowledge. This is followed by further details on the role of the immune system within the primary tumor and the lymph node and the importance of the microenvironment at the metastatic site. The role of the sentinel lymph node in cancer metastasis is emphasized. Special attention is also given to state-of-the-art imaging techniques for the detection of early-stage cancer and cancer metastases, as well as the use of liquid biopsies in sarcoma, prostate, gastrointestinal, and lung cancer. Clinical patterns of malignant tumors arising in different organ systems are compared, described, and discussed with the goal of determining what similarities and/or differences exist. The book concludes with a detailed discussion of surgical intervention, radiation, and systemic therapy of primary and metastatic cancer, and briefly previews several emerging topics, such as the latest findings on personalized cancer therapy, cancer stem cells, unique molecular mechanisms of virus-induced cancer, the impact of the microbiome on cancer metastasis and the application of artificial intelligence in cancer metastasis research. By providing fundamental knowledge of the biological and clinical aspects of cancer metastasis, this book will be an important reference for cancer researchers, clinical oncologists, teachers, and students. Written by experts in the field, each chapter includes a summary of the chapter's key points and open-ended questions that address pressing issues in the field and encourage the reader to consider future directions.

Offering practical, comprehensive coverage of the many nuanced technical and clinical aspects of this growing field, Palliative Radiation Oncology provides up-to-date clinical guidance in a thorough yet concise manner. In an easy-access format, it integrates basic science, pathologies, and research with clinical applications, covering different ways to approach problems, tumor assessment, precise target definition, and dosing-specific guidelines to minimize side effects/toxicities while balancing with desired outcomes. Discusses optimal communication skills for pediatric, adult, and elderly patients. Contains decision-making algorithms to guide individualized palliative radiation oncology treatment plans. Reviews all the latest modalities with technical tips and pitfalls. Covers key procedures such as external beam radiation therapy, intensity modulated radiation therapy, stereotactic body radiation therapy, and stereotactic radiosurgery. Features step-by-step body site-specific guidelines with integrated symptom and toxicity management. Covers symptom and symptom-cluster management, including pain and psychosocial or spiritual distress. Ideal for radiation oncology residents, fellows, and practitioners, as well as medical oncologists, surgical oncologists, oncology nurses, and radiation technicians—all clinicians who work in this highly collaborative, team-based specialty.

This book is structured in three major parts and the first part is a comprehensive overview of IBD-related intestinal cancer. The second and third parts provide rare and important cases on ulcerative colitis (UD) and Crohn's disease (CD) presenting the macroscopic image of the resected specimen and analyzing the endoscopic and the pathological image to explain how to find the IBD cancer. It also delivers a detailed analysis of the histological structure of cancers. This book tries to clarify the critical but yet to be answered questions such as “Why is it so difficult to find out?”, “Why so flat?” and “How to name superficial lesion with invisible margin?” and so on.Atlas of Inflammatory Bowel Disease-Associated Intestinal Cancer is designed to serve all endoscopists and gastroenterologists managing IBD patients. It also is valuable reading for pathologists who are diagnosing gastrointestinal lesions. This book is designed to assist these medical professionals to find cancers in the early stage and stay up-to-date on image-enhanced endoscopy techniques. This book is a translation of an original Japanese edition. This has been facilitated using machine translation (by the service DeepL.com) followed by editors and authors revising, editing and verifying the translated manuscript.

Colorectal cancer (CRC) is a major global health challenge as the third leading cause for cancer related mortalities worldwide. Despite advances in therapeutic strategies, the five-year survival rate for CRC patients has remained the same over time due to the fact that patients are often diagnosed in advanced metastatic stages. Drug resistance is another common reason for poor prognosis. Researchers are now developing advanced therapeutic strategies such as immunotherapy, targeted therapy, and combination nanotechnology for drug delivery. In addition, the identification of new biomarkers will potentiate early stage diagnosis.This book is the third of three volumes on recent developments in colorectal diagnosis and therapy. Each volume can be read on its own, or together. Each volume focuses on different novel therapeutic advances, biomarkers, and identifies therapeutic targets for treatment. Written by leading international experts in the field, coverage addresses the role of diet habits and lifestyle in reducing gastrointestinal disorders and incidence of CRC. Chapters discuss current and future diagnostic and therapeutic options for colorectal cancer patients, focusing on immunotherapeutics, nanomedicine, biomarkers, and dietary factors for the effective management of colon cancer.

This book provides a detailed overview of the activity and efficacy of new treatments and promising perspectives in the field of cutaneous malignancies. The first part of the book covers the basic molecular and immunological mechanisms. It then goes on to cover specific strategies in melanoma and non-melanoma skin cancers that, starting from the basic mechanisms, translate this information into clinical routine or translational research. This unique handbook comprises very practical structured descriptions of more than 10 new agents used in treatment of melanomas and skin carcinomas together with biological background of their mechanisms of action. It provides structured and up-to-date information about all therapeutics in cutaneous malignancies, making it extremely useful in clinical practice, for clinicians that need timely and focused information. Prepared by a group of international authors from expert melanoma centres in Europe, the book provides knowledge distilled from the diverse perspectives of the contributing authors (pathologists, translational scientists and clinicians). This book is of interest to medical oncologists, oncological surgeons, dermatologists and immunologists as well as biologists and pharmacologists.

The new global cancer data suggests that the global burden has risen to 18.1 million new cases per year and 9.6 million cancer deaths per year. A number of factors appear to be driving this increase, in particular, a growing and aging global population and an increase of exposure to cancer risk factors linked to social and economic development. For rapidly-growing economies, the data suggests a shift from poverty- or infection-related cancers to those associated with lifestyles more typical in industrialized countries. There is still large geographical diversity in cancer occurrence and variations in the magnitude and profile of the disease between and within world regions. There are specific types of cancer that dominate globally: lung, female breast and colorectal cancer, and the regional variations in common cancer types signal the extent to which societal, economic and lifestyle changes interplay to deferentially impact on the profile of this most complexgroup of diseases.Unfortunately, despite advances in cancer care, a significant proportion of patients at home, experience sub-optimal outcomes. Barriers to successful treatment outcomes include, but are not limited to: access to oncologists in the primary health centers, non-adherence, lack of experienced oncology and palliative care nurses in the community, inadequate monitoring and the lack of training of family and pediatric physicians. Telemedicine approaches, including telephone triage/education, telemonitoring, teleconsultation and status tracking through mobile applications, have shown promise in further improving outcomes, in particular for chronic cancer patients following their hospitalization. Lessons can be learned from existing hospices in North America, the United Kingdom, Australia, Centers of Excellence in African (Uganda) and modern community services in India (Kerala). An important goal of this book is to describe and encourage professionals to develop new community programs in palliative care, which include training and empowering physicians and nurses in the community on the principles of palliative care. The Middle East Cancer Consortium (MECC) together with the American Society of Clinical Oncology (ASCO) and the American Oncology Nursing Society (ONS) have conducted multiple courses ranging from basic palliative care to more specialized training in palliative care for multiple nationalities in Europe, Asia and Africa. Our experience clearly indicates that, to promote such activities, one needs strong leadership and confirmed political will to support the endeavor. The new book will emphasize the importance of having a core of multiple stakeholders including community leaders, government, NGOs and media to be actively involved in advocating for the cause and generating public awareness.This text will provide the reader with a comprehensive understanding of the outside-of-the-hospital treatment of cancer patients by medical, paramedical and volunteer personnel. In doing so, this text will encourage the creation of new palliative care services improving upon the existing ones and stimulate further research in this field.Part 1 of the text will begin with an overview of the current state of affairs of services provided to cancer patients while being cared for by primary health centers. It will also review the current literature regarding medical and psychological-based therapy options in the community for cancer patients at different stages of their disease. Part 2 will address the unique role of the community nurse, within the framework of the multidisciplinary team treating the patient, in the attempt to provide optimal evaluation and care in very challenging situations (such as with terminal patients). Part 3 will provide insightful models

This textbook provides a practically applicable resource for understanding the surgical oncology management of pancreatic cancer. It discusses relevant aspects of anatomy and pathophysiology along with the latest diagnostic techniques. Insightful descriptions are then provided detailing how to perform critical surgical procedures when treating these patients. Relevant perioperative management strategies and emerging themes in cancer biology critical to understanding and treating the disease are also described. The need for cross-discipline collaboration to facilitate and enhance innovation within the discipline is reinforced throughout the text. Each chapter presents the relevant current clinical standards along with areas of controversy in both research and clinical practice within “pearls and pitfalls” sections. Textbook of Pancreatic Cancer: Principles and Practice of Surgical Oncology is a detailed work covering the basic material important to trainees as well as advanced curriculum for established specialists in the field from a multi-disciplinary perspective. Therefore, it is crucial resource for all practicing and trainee professionals who encounter these patients in their day-to-day clinical practice.

This book covers relevant concepts in nuclear cardiology, combining imaging techniques and clinical data to do so. Today, nuclear cardiology is a worldwide discipline connected to the broader field of cardiovascular imaging. The combination of clinical aspects (symptoms, medications, previous cardiac procedures), ancillary exams and nuclear images is key to decision-making in clinical practice. Thus, a book on this topic is essential to provide better outcomes for cardiology patients. The chapters cover a comprehensive range of topics in current cardiology practice, such as ambulatory patients, patients in emergency settings, patients after complex cardiac procedures, and patients during and after the use of cancer therapies that are potentially toxic for the heart (cardio-oncology). As such, multiple clinical scenarios are also presented: patients with suspected coronary disease, patients with heart failure of unknown origin, patients with acute chest pain in the emergencydepartment, patients with suspected pulmonary embolism, patients with complications of the left ventricular assist device, etc. Furthermore, the book describes nuclear cardiology procedures and techniques, discusses the main clinical indications and scenarios for each procedure, presents new technological advances in the field (machine learning and artificial intelligence tools), and mentions the coronavirus disease 2019 (COVID-19) pandemic. Given its scope, the book offers a valuable guide and videos for various medical professionals, especially cardiologists and nuclear physicians.

The second edition of Genetic Counseling Practice: Advanced Concepts and Skills, provides in-depth content regarding the advanced competencies for meeting patient needs across the changing landscape of genetic counseling practice. The content aligns with the Reciprocal Engagement Model (REM) of practice which integrates the biomedical knowledge and psychosocial aspects of genetic counseling. This edition has been revised and expanded to reflect advances made in the present-day field. Edited by a team two genetic counselors and a psychologist, the chapters offer a holistic picture of genetic counseling. Chapter authors are all recognized experts in the profession. The chapters are grounded in evidence-based practice and research. Each chapter includes learning activities to help readers apply concepts and skills. Featured topic areas include: Meeting the needs of culturally diverse patients Addressing challenging patient dynamics Working with children, adolescents and families Using emerging service delivery models for genetic counseling Engaging in self-reflective, deliberate practice Promoting genetic counselor professional development Genetic Counseling Practice is an indispensable guide to the complex and evolving field of genetic counseling, and this updated second edition will help practitioners and trainees alike navigate its most pressing and practical challenges with skill and care.

Revealing essential roles of the tumor microenvironment in cancer progression, this book provides a comprehensive overview of the latest research on the role of interleukins in the tumor microenvironment. Each chapter focuses on the various ways to target the tumor microenvironment by intervention in the interleukin biology, including IL-1, IL-8, IL-21, IL-36 signaling, and more. Taken alongside its companion volumes, Tumor Microenvironment: The Role of Interleukins – Part A updates us on what we know about various aspects of the tumor microenvironment, as well as future directions. This book is essential reading for advanced cell biology and cancer biology students as well as researchers seeking an update on research in the tumor microenvironment.

This book is intended as a comprehensive resource for clinicians and researchers seeking in-depth information on geriatric oncology. The coverage encompasses epidemiology, the biology and (patho)physiology of aging and cancer, geriatric assessment and management, hematologic malignancies, solid tumors, issues in patient care, and research methods. Since cancer is a disease of aging and people are living longer, most cancer patients are now aged 70 and older. Yet the more we age, the more diverse we become in terms of our health, biologic fitness, and cancer behavior. Typically, however, general oncology clinical trials address only a selected healthier and younger population of patients. Geriatric oncology is the area of oncology that addresses these issues but while a wealth of knowledge has been accumulated, information is often difficult to retrieve or insufficiently detailed. The SpringerReference program, in which this book is published, offers an ideal format for overcoming these limitations since it combines thorough coverage with access to living editions constantly updated chapter by chapter via a dynamic peer-review process, ensuring that information remains current and pertinent.

This book offers a comprehensive review of Lynch Syndrome (LS), addressing both the basic and clinical aspects of this condition. Due to the recent advances in our understanding of the genetic mechanism of LS, and to new screening methods, including universal screening and/or multi-gene panel analysis, the standard treatment strategy for patients and family members of LS have been steadily improving. In this book, experts describe the disease's manifestations, discuss state-of-the-art diagnosis and management options, and offer a cutting-edge overview of the genetic and epigenetic basis of the syndrome. Providing essential insights into this new phase in the management of LS, this book is a valuable resource not only for colorectal surgeons, but also for general gastrointestinal clinicians, gynecologists, oncologists and all basic researchers with an interest in LS.

Tumors/cancers are characterized by uncontrolled growths of abnormal cells that extend beyond their usual boundaries and disrupt the normal functions of affected organs and systems. While about 75%–80% of tumors/cancers arise sporadically without a family connection, 20%–25% appear to be familial (including 10%–15% nonhereditary familial tumors [or familial tumors] and 5%–10% hereditary familial tumors [or hereditary tumors]). As nonhereditary and hereditary familial tumors often show both tumor-related and non-tumor-related (or syndromic) symptoms, they are referred to as tumor syndromes (or cancer susceptibility syndromes). In comparison with sporadic tumors/cancers, tumor syndromes (>300 described so far) tend to occur at a younger age, involve multiple organs and systems, produce multiple (often in a distinct spectrum) and bilateral lesions, form multiple hamartomatous, benign, or precursor lesions; locate in specific site(s), display unique syndromic features, and affect multiple members/generations of a family. This book provides state-of-art and authoritative coverage of nearly 100 tumor syndromes, with chapters presenting overviews of individual tumor syndromes in relation to their biology, epidemiology, pathogenesis, clinical features, diagnosis, treatment, and prognosis. Featuring contributions from oncologists, clinicians, and specialists, the book offers a reliable, comprehensive reference on tumor syndromes for scholars and students of medicine, dentistry, pharmacology, nursing, public health, and other biomedical disciplines.Key Features Reviews the biology, epidemiology, pathogenesis, and clinical features of tumor syndromes Contains up-to-date information on the diagnosis and treatment of tumor syndromes Includes expert coverage from leading oncologists and clinicians Related TitlesJ. R. McIntosh, Understanding Cancer: An Introduction to the Biology, Medicine, and Societal Implications of This Disease (ISBN 978-0-8153-4535-0)P. S. T. Shanmugam, Understanding Cancer Therapies (ISBN 978-1-1381-9815-9)J. M. Baehring and J. M. Piepmeier, eds., Brain Tumors: Practical Guide to Diagnosis and Treatment (ISBN 978-0-3673-9022-8)D. Liu, Tumors and Cancers: Endocrine Glands – Blood – Marrow – Lymph (ISBN 978-1-4987-2975-8)Dongyou Liu, PhD, has worked at several research and clinical laboratories in Australia and the United States for the past three decades, with a focus on molecular characterization of microbial pathogens and detection of human genetic disorders and tumors/cancers. He is the primary author of more than 50 original research and review articles in various peer-reviewed international journals, the contributor of 197 book chapters, and the editor of more than 10 books.

This book explains the immunology of organ-specific malignancies and discusses novel immunotherapy strategies for their treatment. Since the first, very successful edition of the book was published in 2015, a number of entirely new chapters have been included. The range of cancers considered has accordingly been extended, with coverage of the latest immunotherapy approaches for cancers in different organs. In addition, the original chapters have been updated to document the latest advances in immunotherapy for pediatric solid tumors, hematologic malignancies, gastrointestinal tumors, bone tumors, central nervous tumors, lung cancer, genitourinary tract tumors, and breast cancer, among others. The book is published as part of the three-volume Springer series Cancer Immunology, which aims to provide an up-to-date, clinically relevant review of cancer immunology and immunotherapy. Other volumes in the series address the translational medicine context and bench to bedside immunotherapy. Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors will be of special value to clinical immunologists, hematologists, and oncologists.

This thoroughly revised second edition is an up-to-date overview of the new advances in the knowledge of the basic science in sarcoma and osteosarcoma. It features detailed, in-depth discussions of microRNAs in osteosarcoma, historical perspectives of chemotherapy in the treatment of the disease, tumor targeted IL12 therapy and HER2 targeted therapy, the role of enhancer elements in regulating the prometastatic transcriptional program and more. Further, this essential volume also includes new insights on Wnt signaling in osteosarcoma, the role of genomics, genetically modified T-cell therapy, liquid biopsy, oncolytic viruses, immunophenotyping, receptor tyrosine kinases and epigenetic-focused approaches for treatment of osteosarcoma metastases, as well as thoughts on the current standard of treatment for patients suffering from these cancers. In the years since the previous edition, there have been numerous new developments in this rapidly changing field; this new edition is both timely and urgently needed. When taken together these companion volumes, Current Clinical (Book 1) and Scientific (Book 2) Advances in Osteosarcoma, are a timely and urgently needed guide for laboratory investigators and clinical oncologists.

Revealing essential roles of the tumor microenvironment in cancer progression, this book provides a comprehensive overview of the latest research in the field. A variety of topics are covered, including metabolism in the tumor microenvironment, stellate cells and endothelial progenitors in the tumor microenvironment, as well as the effects of HIV, viral hepatitis, and inflammation in the tumor microenvironment, and more. Taken alongside its companion volumes, Tumor Microenvironment: State of the Science updates us on what we know about various aspects of the tumor microenvironment, as well as future directions. This book is essential reading for advanced cell biology and cancer biology students as well as researchers seeking an update on research in the tumor microenvironment.

Publisher's Note: Products purchased from 3rd Party sellers are not guaranteed by the Publisher for quality, authenticity, or access to any online entitlements included with the product. Now updated online for the life of the edition, DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 11th Edition keeps you up to date in this fast-changing field. Every quarter, your eBook will be updated with late-breaking developments in oncology, including new drugs, clinical trials, and more.

This book addresses key issues of controversy in radiation oncology for each disease site, with expert commentaries from leading authorities in the field. It identifies areas of confusion arising from discrepant data in the literature regarding certain clinical scenarios for different diseases and presents high-level evidence on each issue with a view to fostering best practice. Controversies in Radiation Oncology will serve as a very useful resource for busy radiation oncology physicians, practitioners, and trainees/residents/fellows seeking to utilize evidence in the literature to guide the management of radiation therapy patients.

This comprehensive volume reviews the clinical presentation, diagnosis, and treatment approach to rare lymphomas. There is particular emphasis placed on new diagnostic approaches, novel chemotherapy combinations, and treatment modalities with novel therapeutics. It highlights research advances in a group of diseases that are often overlooked, and serves as a single repository of information on the most recent advances in targeted small molecule inhibitors, monoclonal antibodies, immunotherapy, and CAR-T therapy as they pertain to rare types of lymphoma. Written for practicing oncologists, hematologists, fellows, and residents, Novel Therapeutics for Rare Lymphomas covers rare subtypes of lymphoma, including indolent and aggressive T-cell lymphomas and B-cell lymphomas.

This book offers a comprehensive review of recent advances in cancer immunotherapy, and explores the value and limitations of the most effective current therapeutic strategies and emerging treatment modalities. It discusses in detail the successes achieved using monoclonal antibodies (mAbs), including developments with regard to conjugated mAbs and also bispecific mAbs as novel treatment options for leukemia and solid tumors. It also examines the advances toward personalized immunotherapy, focusing on the effectiveness of adoptive cell therapy using genetically engineered T cells with tumor-associated antigen-specific T-cell receptors and chimeric antigen receptors, as well as the role of tailored vaccines based on the patient's cancer mutanome. Further, it describes the impressive therapeutic results recently achieved with checkpoint inhibitors, and analyzes novel strategies to modulate the immunosuppressive tumor microenvironment. Written by leading international experts and providing up-to-date information on emerging strategies, such as oncolytic virus-based therapy, epigenetic therapy, and combination therapy, the book appeals to all those with an interest in immunotherapy as it comes of age.

Oncogenomics: From Basic Research to Precision Medicine offers a thorough survey of precision medicine and its diagnostic and therapeutic applications in oncology. Gathering contributions from leading international researchers in the field, chapters examine recent translational advances in oncogenomic methods and technologies, detailing novel molecular classifications of tumors as well as diagnostic and prognostic biomarkers for various types of cancers including pancreatic, gastrointestinal, breast, hematological, lung, osteotropic, genitourinary, and skin cancers. This book provides a foundation for clinical oncologists, human geneticists, and physicians to develop new targeted cancer treatments and incorporate genomic medicine into clinical practice, with particular attention paid to noninvasive diagnostic techniques such as the liquid biopsy and molecular characterization of solid malignancies. Provides clinical oncologists, human geneticists, physicians, and students with a thorough understanding of current diagnostic and prognostic applications of genomic methods and technologies to a variety of solid malignancies Employs current knowledge in oncogenomics towards developing therapeutic interventions for various cancer types Features a team of internationally recognized researchers and physicians in clinical oncology, oncogenomics and precision medicine

This book explores topics of importance to all who have an interest in economic methods for assessment of the efficacy and effectiveness of new cancer treatments and in regulatory measures relating to their marketing authorization and pricing. Targeted therapies and modern immunotherapy are placing a substantial strain on health care budgets. Regulation and economic methods to assess the parameters for establishing efficacy and effectiveness are therefore of prime importance. Payer authorities have to determine whether the use of these novel therapies yields clinical benefits that justify their increasing cost. In the simplest terms, cost-effectiveness analyses quantify the ratio between the extent to which an intervention raises healthcare costs and the extent to which it improves health outcomes. Rigorous cost-effectiveness analyses translate all health outcomes into quality-adjusted life years. On the other hand, in order to sustain innovation, price regulations must be coupled with efforts to ensure that drug companies are still able to recoup their investments in high-risk and high-costs research programs. Ultimately, decisions regarding health care expenditures are also a question of society's willingness to pay.

With advances in technology and medical science, children with previously untreatable and often fatal conditions, such as congenital heart disease, extreme prematurity and pediatric malignancy, are living longer. While this is a tremendous achievement, pediatric providers are now more commonly facing challenges in these medical complex children both as a consequence of their underlying disease and the delivery of medical care. The term healthcare-associated infections (HAIs) encompass both infections that occur in the hospital and those that occur as a consequence of healthcare exposure and medical complexity in the outpatient setting. HAIs are associated with substantial morbidity and mortality for the individual patient as well as seriously taxing the healthcare system as a whole. In studies from the early 2000s, over 11% of all children in pediatric intensive care units develop HAIs and this figure increases substantially if neonatal intensive care units areconsidered. While progress has been made in decreasing the rates of HAI in the hospital, these infections remain a major burden on the medical system. In a study published in 2013, the annual estimated costs of the five most common HAIs in the United States totaled $9.8 billion. An estimated 648,000 patients developed HAIs in hospitals within the US in 2011 and children with healthcare-associated bloodstream infection have a greater than three-fold increased risk of death.While a number of texts discuss HAIs in the broader context of infectious diseases or pediatric infectious diseases (such as Mandell's Principles and Practice of Infectious Diseases or Long and Pickering's Principles and Practice of Pediatric Infectious Diseases) no single text specifically focuses on the epidemiology, diagnosis and management of HAI in children. Many infectious diseases texts are organized based on the microbiology of infection and from this starting point then discussing the clinical syndromes associated with the organism of interest. For instance, a chapter on Staphylococcus aureus may contain a brief discussion of the role of S. aureus in surgical site infections in the wider context of all staphylococcal disease. For clinicians caring for children at the bedside, however, the clinical syndrome is typically appreciated and intervention necessary prior to organism identification. We propose a text that details both the general principles involved in HAIs and infection prevention but also provides a problem oriented approach. Such a text would be of interest to intensivists, neonatologists, hospitalists, oncologists, infection preventionists and infectious diseases specialists. The proposed text will be divided into three principle sections: 1) Basic Principles of Infection Control and Prevention, 2) Major Infectious Syndromes and 3) Infections in Vulnerable Hosts. Chapters in the Major Infectious Syndromes section will include discussion of the epidemiology, microbiology, clinical features, diagnosis, medical management (or surgical management as appropriate) and prevention of the disease entity of interest. Chapters will seek to be evidenced based as much as possible drawing from the published medical literature as well as from clinical practice guidelines (such as those from the Infectious Diseases Society of America) when applicable. We intend to include tables, figures and algorithms as appropriate to assist clinicians in the evaluation and management of these often complex patients. Finally, we intend to invite authors to participate in this project from across a number of medical specialties including infectious diseases, infection control, critical care, oncology and surgery to provide a multidisciplinary understanding of disease. It is our intent to have many chapters be co-written by individuals in different subspecialties; for instance,a

This book provides a comprehensive and up-to-date overview of major technical advances and research findings in the field of brachytherapy. Especially research conducted on brachytherapy in Japan has made tremendous strides, offering readers valuable insights into new treatment outcomes, evidence and techniques. In the respective chapters, each author elucidates cutting-edge findings, addressing both the basic and clinical aspects including the application to various cancers, and especially focusing on highly valuable data gleaned in Japan. As such, the book will benefit not only radiation oncologists but also basic researchers, radiation technologists, medical physicists and members of medical staff who are involved in the development and utilization of this advanced therapy.

Encyclopedia of Cancer, Third Edition, Three Volume Set provides a comprehensive, up-to-date overview of the multiple facets of the disease, including research, treatment and societal impact. This new edition comprises 180 contributions from renown experts who present the latest in Mechanisms, Hallmarks of Cancer, Causes of Cancer, Prevention and Control, Diagnosis and Therapy, Pathology and the Genetics of specific Cancers. Readers will find a comprehensive overview of the main areas of oncology, including etiology, mechanisms, prevention, and treatments, from basic science to clinical applications and public health, all set alongside the latest advances and hot topics that have emerged since the previous edition. Topics of interest in the field, including genomics and epigenomics, our understanding of the causes of cancer and the approaches to preventing it (e.g., HPV vaccination, role of obesity and nutrition, molecular markers of environmental exposures), new screening techniques (e.g., low-dose CT for lung cancer) and improvements in the treatment of many cancers (e.g., breast cancer, lung adenocarcinoma) are comprehensively and authoritatively presented. Comprises 180 contributions from renowned experts who present the latest in mechanisms, hallmarks of cancer, causes, prevention and control, diagnosis and therapy, pathology and genetics Presents a comprehensive overview of the main areas of oncology, including etiology, mechanisms, prevention, and treatments, from basic science to clinical applications and public health

Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms'emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials. Summarizes the sensitizing role of some tyrosine kinase inhibitors in existing research Brings recent findings in several cancer types, both experimental and clinically, with a particular emphases on underlying biochemical, genetic, and molecular mechanisms Provides an updated and comprehensive knowledge regarding the field of combinational cancer treatment

This volume takes a closer look how the cell organelles Golgi apparatus (also known as the Golgi complex or Golgi body), and centriole are structurally and functionally intertwined.Initially, it was believed that the role of Golgi complex is limited to the packaging and preparation for secretion of various cellular proteins, while the centriole participates in cell division and cilia formation. However, since their discovery nearly 200 years ago, it became clear that these two organelles are interacting, and that their functions are much more complex and far reaching than previously thought. Recent findings indicate that the Golgi–Centriole relationship may be important for directional protein transport, cell polarization and cell cycle progression. Current studies indicate that Golgi and centriole also participate in development and act as cellular and immunological sensors, and that their abnormalities lead to cell and developmental abnormalities, Alzheimer, cancer, variouslipid disorders and neurological and immunological diseases in humans. This volume combines the latest information on the structure, molecular composition, and roles of Golgi and centriole in various cellular functions and diseases. The better understanding of the Golgi–centriole interactions may lead to the development of novel therapies for the treatment of various diseases, including cancer.

This comprehensive text focuses exclusively on the management of metastatic spinal disease, evaluating the most recent literature and providing patient-centered treatment algorithms. Beginning with initial imaging, classification and clinical decision-making, the spine is approached anatomically from the upper cervical to the sacrum, describing the unique considerations and approaches appropriate to each region, such as laminectomy and stabilization, en bloc spondylectomy and resection and reconstruction. Less invasive and minimally invasive approaches are discussed throughout the text. Radiation therapy modalities and other adjuvant treatments are also discussed, as well as reconstructive flap coverage and the management of complications. The spinal column is the most common site of metastatic cancer, and a multidisciplinary approach is required to provide patients with reasonable management options to prevent and treat the disabling symptoms caused by this debilitatingcondition. This compendium of experience from thought leaders in the treatment of metastatic spine disease will provide spine surgeons, oncologists, radiation oncologists, physiatrists and palliative care specialists with up-to-date information to guide their patients through the multidisciplinary management of metastatic spinal disease.

This book discusses major issues and advances in the diagnosis and treatment of incidentally detected early-stage lung cancer (ESLC). In Part I, pathology and radiology experts comprehensively review the state-of-the-art advances in individual research fields, and offer an update on the cross-sectional anatomy of the lung and post-processing techniques for CT imaging. Part II focuses on the imaging features, differential diagnosis and radiologic-pathologic correlations of ESLCs in the categories pGGN, mGGN and solid nodules in compliance with the Guidelines on Lung Cancer Screening from the National Comprehensive Cancer Network (NCCN). Part III briefly introduces therapeutic management strategies for ESLCs, including surgical and non-surgical approaches, for instance stereotactic ablative radiation therapy (SABR) and radiofrequency ablation (RFA). Lastly, the authors have meticulously prepared 50 clinical cases of pathologically proven benign and malignant pulmonary nodules with in-depth discussion and experts'comments to further readers'understanding of practical imaging and management strategies of ESLCs.

The second edition of Oncology Clinical Trials has been thoroughly revised and updated and now contains the latest designs and methods of conducting and analyzing cancer clinical trials in the era of precision medicine with biologic agents—including trials investigating the safety and efficacy of targeted therapies, immunotherapies, and combination therapies as well as novel radiation therapy modalities. Now divided into six sections this revamped book provides the necessary background and expert guidance from the principles governing oncology clinical trials to the innovative statistical design methods permeating the field; from conducting trials in a safe and effective manner, analyzing and interpreting the data, to a forward-looking assessment and discussion of regulatory issues impacting domestic, international, and global clinical trials.Considered by many as the gold standard reference on oncology clinical trials in the field, the second edition continues to provide examples of real-life flaws and real-world examples for how to successfully design, conduct and analyze quality clinical trials and interpret them. With chapters written by oncologists, researchers, biostatisticians, clinical research administrators, and industry and FDA representatives, this volume provides a comprehensive guide in the design, conduct, monitoring, analysis, and reporting of clinical trials in oncology.NEW TO THIS EDITION:Outlines how to design clinical trials with and without biomarker testing—including genomics-based “basket” trials, and adaptive trials for all phases during treatment and quality-of-life trialsIncludes new chapters on immunotherapy trials, radiation therapy trials, multi-arm trials, meta-analysis and adaptive design, use of genomics, dose modifications and use of ancillary treatments in investigational studies, establishing surrogate endpoints, practical issues with correlative studies, cost-effectiveness analysis, and moreComprehensively covers all regulatory aspects in the pursuit of global oncology trialsDigital access to the ebook included

Publisher's Note: Products purchased from 3rd Party sellers are not guaranteed by the Publisher for quality, authenticity, or access to any online entitlements included with the product. This extensive title, which combines scientific principles with up-to-date clinical procedures, has been thoroughly updated for the fourteenth edition. You'll find in-depth material on the biology and pathophysiology of lymphomas, leukemias, platelet destruction, and other hematological disorders as well as the procedures for diagnosing and treating them.

Get a quick, expert overview of the many key facets of lung cancer evaluation and management with this concise, practical resource by Drs. Lynn T. Tanoue and Frank Detterbeck. This easy-to-read reference presents a summary of today's best evidence-based approaches to diagnosis and management in this critical area. Covers diagnosis and evaluation, treatment considerations, and comprehensive care options for patients with lung cancer. Provides insight on evidence for today's best practices, as well as future directions in the field. Consolidates today's evidence-based information on the clinical aspects of lung cancer into one convenient resource.

Acute Leukemia: An Illustrated Guide to Diagnosis and Treatment provides a comprehensive and concise visual reference on acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) seen in children and adults. This book addresses all aspects of AML and ALL including their risk factors, cytogenetics and mutational characteristics, diagnoses, clinical management and prognoses which are imperative and challenging for medical students, residents, hematology and medical oncology fellows, and even community oncologists and hematologists. It presents complex information relying predominantly on pictorial depictions rather than traditional text in a visually instructive format. It replaces the wordiness of a traditional textbook with original and adapted illustrations, instructive schemata and diagrams, photomicrographs, tables, detailed figure legends, and practical, ‘bite-sized'text. The result is a visually engaging book that is easy to read, review, and remember.Crafted by world experts in the field, this digestible volume provides you with the must-know information that you can utilize when encountering AML and ALL patients who require immediate attention. Whether you are an early-career practitioner looking for quick guidance to managing a deadly disease or you are a seasoned clinician looking for a quick review of treatment protocols, this engaging format provides a unique and ‘go-to'resource.Key Features:Contains over 40 tables and over 220 illustrations, histologic photomicrographs, flow diagrams, graphs, and schemata with detailed figure legendsPresents complex scientific aspects such as cytogenetics and molecular mutations in a visually digestible and easy-to-understand formatProvides helpful and evidence-based treatment recommendations when providing induction therapy, consolidation therapy, and bone marrow transplantationIncludes unique chapters on managing psychosexual issues accompanying AML and ALL treatment as well as on the FDA drug development and clinical trial design processIncludes digital access to the e-book as well as an online Image Bank

This book examines the latest indications and techniques for various endoscopic and surgical colorectal cancer treatments, discussing not only on the standard lymph node dissection technique, but also on laparoscopic and robotic surgery. It particularly focuses on the treatment of rectal cancer, with chapters on radiation therapy and sphincter preservation, which is analyzed from Asian perspectives that differ from those of Western treatment. Further, it presents the results of combining chemotherapy and oral drugs, as well as the treatment of hereditary cancer using next-generation sequencing for genetic diagnosis.Edited by surgeons who have pioneered the research and treatment of colorectal cancer, Recent Advances in the Treatment of Colorectal Cancer presents extensive information for clinicians such as endoscopic surgeons, colorectal surgeons, as well as oncologists and researchers specializing in this field. Providing a foundation for new ideas, it enables advanced surgeons to further develop their skills and offers thought-provoking, instructive and informative reading for residents, students and medical staff.

This text serves as a very useful clinical guide and realistic approach to the clinical management of melanoma. Primary care physicians, specialists from varying areas of medical practice and numerous other healthcare providers will find this text to be quite useful as a standard daily reference and use in the office setting. It provides a clear and concise source of information in order to make real-life, evidence-based decisions for all aspects of management for cutaneous melanoma. This book also provides the latest breakthroughs in melanoma research, ranging from recent discoveries in genomics and epigenetics, to newly identified genes that have been selectively targeted for the development of a personalized approach to treatment. All chapters are written by specialists and true experts within their respective fields, incorporating the latest scientific, clinical and evidence-based medicine for melanoma (and non-melanoma skin cancers). This up-to-date information can be easily applied and translated to the clinical setting for the melanoma patient.

This book provides information on a wide variety of issues ranging from genetics to clinical description of the syndromes, genetic testing and counseling, and clinical management including surveillance, surgical and prophylactic interventions, and chemoprevention. Moreover, current hot issues, such as the identification of novel causal genes and the challenges we face, and the relevance of cancer risk modifiers, both genetic and environmental, are also discussed. This reference book is great for geneticists, oncologists, genetic counselors, researchers, clinicians, surgeons and nurses dedicated to, or interested in, hereditary cancer. The best and most recognized experts in the field have contributed to this project, guaranteeing updated information, accuracy and the discussion of topical issues.

The new edition of this textbook integrates the history, epidemiology, pathology, pathophysiology, therapeutics, and supportive care of modern neoplastic hematopathology. Now in its sixth edition, this classic and invaluable text brings together a team of internationally renowned experts and offers in-depth coverage of the complex interface between diagnosis and therapy. The textbook is divided into five major sections, with the first four covering the spectrum of hematologic neoplasia, including chronic leukemias and related disorders, acute leukemias, myeloma and related disorders, and lymphomas, and the fifth section covering a variety of topics in supportive care. Chapters are presented in an accessible and easy-to-read layout, providing updates on the tremendous progress made in the last decade in the understanding of the nature of hematologic malignancies and their treatment.Neoplastic Diseases of the Blood, Sixth Edition is an authoritative and indispensable resource for students, trainees, and clinicians, sure to distinguish itself as the definitive reference on this subject.

This volume provides summarized scientific evidence of the different classes of plant-derived phytocompounds, their sources, chemical structures, anticancer properties, mechanisms of action, methods of extraction, and their applications in cancer therapy. It also discusses endophyte-derived compounds as chemopreventives to treat various cancer types. In addition, it provides detailed information on the enhanced production of therapeutically valuable anticancer metabolites using biotechnological interventions such as plant cell and tissue culture approaches, including in vitro-, hairy root- and cell-suspension culture; and metabolic engineering of biosynthetic pathways. Anticancer Plants: Natural Products and Biotechnological Implements – Volume 2” explores the natural bioactive compounds isolated from plants as well as fungal endophytes, their chemistry, and preventive effects to reduce the risk of cancer. Moreover, it highlights the genomics/proteomics approaches and biotechnological implementations. Providing solutions to deal with the challenges involved in cancer therapy, the book benefits a wide range of readers including academics, students, and industrial experts working in the area of natural products, medicinal plant chemistry, pharmacology, and biotechnology.